The reiteration of a Buy rating and maintenance of a $23 price target by a reputable analyst like Robyn Karnauskas from Truist Securities could positively influence investor sentiment towards Roivant Sciences. This endorsement reaffirms the analyst's confidence in the company's potential, likely encouraging both current and potential investors. The specific mention of the price target provides a clear benchmark for expectations, further solidifying the positive outlook.